AstraZeneca's Arimidex has been granted a new indication by the UK's Medicines and Healthcare products Regulatory Agency. The new indication "will mean that more postmenopausal women whose breast cancer is fueled by the hormone, oestrogen -- about 75 percent of all postmenopausal cases -- are now eligible to receive Arimidex after surgery to prevent their disease returning." Story